Bevacizumab

Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases

...ing use of anti-VEGF antibodies in children, Dr. Avery sounds a cautious note. One study, also published in the August Journal of AAPOS , found that bevacizumab treatment in one eye of a child with eye disease also improved the condition in the other eye. This, along with other limited reports, suggests that ...

Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients

... SAN FRANCISCO (August 1, 2009)Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer....

Cancer treatment controls macular edema related to diabetes and to cataract surgery

...erican Academy of Ophthalmology, reports on use of bevacizumab (Avastin), to benefit diabetic patients with macul...elop cystoid macular edema after cataract surgery. bevacizumab is also used to treat some cancers. Another study ...d other standard treatments. Treating DMME with bevacizumab (Avastin), an anti-vascular endothelial growth fac...

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29

...d non-small cell lung cancer (NSCLC). The Company also noted that the data from Phase 2 study evaluating motesanib in combination with chemotherapy or bevacizumab in combination with chemotherapy will be presented at the World Conference on Lung Cancer. Motesanib is part of a broad co-development program between...

Anti-angiogenesis treatment improves hearing in some NF2 patients

... Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in ...m Massachusetts General Hospital (MGH) report that bevacizumab treatment successfully shrank characteristic tumor...embers of the research team offered treatment with bevacizumab (Avastin), which is FDA-approved for treatment of ...

Drug Shows Promise in Nervous-System Tumor Treatment

...und that treatment with the angiogenesis inhibitor bevacizumab (Avastin) shrank vestibular schwannomas, improved ...aring and eased other symptoms in NF2 patients. bevacizumab is an anti-cancer drug designed to reduce blood fl...lood vessel development. They then decided to test bevacizumab in 10 NF2 patients with vestibular schwannomas. ...

Drug Combo Proves Powerful Against Lung Cancer

...had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the d... grew worse, compared with 3.7 months for those on bevacizumab alone. Non-small cell lung cancer, often linke...

Study shows drug combination improves outcome for advanced non-small cell lung cancer

...va), a targeted agent, to maintenance therapy with bevacizumab (Avastin), an agent commonly used as a component o... In total, 768 patients were randomized to receive bevacizumab plus erlotinib or bevacizumab plus placebo after initial cytotoxic chemotherapy ...

Avastin Unsuccessful as Adjuvant Therapy in Setting of Stage II and III Colon Cancer but May Be Effective if Given for Longer Duration

...merican Society of Clinical Oncology (ASCO) in Orlando that use of the drug bevacizumab (Avastin) in combination with standard chemotherapy was not effective in pr...merican Society of Clinical Oncology (ASCO) in Orlando that use of the drug bevacizumab (Avastin) in combination with standard chemotherapy was not effective in pr...

1 in 10 advanced colon cancer patients worry about prescription drug costs

... Cancer Leukemia Group B (CALGB) Phase III clinical trial that compared outcomes of patients who received combination chemotherapy in conjunction with bevacizumab and cetuximab together or with cetuximab alone. The participants also received prescriptions for "supportive" drugs, such as anti-nausea medications, ...

Bevacizumab in Medical Technology

First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer

Collaborative groups set out to confirm potential benefits of anticancer therapies to treat women with breast cancer PARIS, May 27 /PRNewswire/ -- A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuz...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

SAN FRANCISCO, April 14 /PRNewswire-FirstCall/ -- Positive preclinical data was presented by Nektar Therapeutics (Nasdaq: NKTR ) this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse xenograft model of colorectal canc...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...n approved drugs for patients with metastatic colorectal cancer: 5-FU, capecitabine (Xeloda(R)), irinotecan (Camptosar(R)), oxaliplatin (Eloxatin(R)), bevacizumab (Avastin(R)), cetuximab (Erbitux(R)), and panitumumab (Vectibix(R)). Depending on the stage of the cancer, two or more of these types of treatment ma...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...n approved drugs for patients with metastatic colorectal cancer: 5-FU, capecitabine (Xeloda(R)), irinotecan (Camptosar(R)), oxaliplatin (Eloxatin(R)), bevacizumab (Avastin(R)), cetuximab (Erbitux(R)), and panitumumab (Vectibix(R)). Depending on the stage of the cancer, two or more of these types of treatment ma...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...lanoma treated with everolimus in combination with bevacizumab experienced a clinical benefit (4% had a partial r...stable disease). The combination of everolimus and bevacizumab was generally well tolerated. According to the abs...FL. Hainsworth J et al. Phase II trial of bevacizumab and everolimus in the treatment of patients with m...

New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

... the FinXX-trial. Avastin Smith IE et al Primary analysis of study MO19391, an Saturday open-label safety study of bevacizumab 13th, plus taxane-based therapy as 1st-line December treatment of patients with locally 07:00...

First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval

...h Non Small Cell Lung Cancer each year in the United States, with an estimated 60,000 patients per year potential candidates for targeted therapy with bevacizumab in the United States. Data presented in peer reviewed publications has shown that two blinded expert observers, when asked to give an independent hi...

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

...ar), inhibitors of the mammalian target of rapamycin, such as temsirolimus (Torisel), and the anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab (Avastin). Although each agent can provide some benefit in a subset of patients, complete response is exceedingly rare, and most patients with metasta...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

...II trial of weekly administration of nabpaclitaxel in combination with bevacizumab in women with metastatic breast cancer (MBC) -- Mary Ann Allison, M....ar cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab -- Kelly Pendergrass, M.D., Kansas City Cancer Center-South: Charact...

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

...static breast cancer is warranted. Lapatinib and bevacizumab in HER2+ metastatic breast cancer: abstract 1042(2...m this study demonstrate that TYKERB combined with bevacizumab provided patients with a 34.4 percent clinical ben...g of TYKERB administered orally daily and 10 mg/kg bevacizumab IV every two weeks. The most common adverse events...

Bevacizumab in Biological News

Biomarkers allow doctors to match therapy to patient

...r the effectiveness of treatment with sunitinib or bevacizumab for kidney and non-small cell lung cancer. Ou...lial growth factor (VEGF) receptor targeted agents bevacizumab and sunitinib have proven effective against severa...45neg, CD34bright and CD133neg during sunitinib or bevacizumab treatment. They labeled them candidate cells b...

Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer

...of the body ?show that those patients who received bevacizumab (Avastin? in combination with standard chemotherap..., Calif., which manufactures bevacizumab, provided bevacizumab for the trial under the Cooperative Research and D...ts suggest that patients in the study who received bevacizumab in combination with standard chemotherapy consisti...

Bevacizumab in Biological Technology

Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting

... -- Poster 44E, Abstract #9603, Saturday, May 31, 2008, 2:00 - 6:00 p.m., S Hall A1 -- Updated results of a Phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell carcinoma (RCC) -- Jeffrey Sosman, MD, professor of medicine (hematology/oncology), Vanderbilt-I...

Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx

... with the anticancer drug gemcitabine (Gemzar(R)) in patients with metastatic breast cancer whose cancer has progressed during or after treatment with bevacizumab (Avastin(R)). (Logo: http://www.newscom.com/cgi-bin/prnh/20071112/CLM151LOGO ) The double-blind, randomized trial will enroll a total of 220 pat...

ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer

...ing investigated in a pivotal Phase 3 study, with 5-fluorouracil (5-FU) and bevacizumab for the initial treatment of metastatic colorectal cancer. CoFactor is a fo...in combination with the widely used cancer chemotherapy regimen of 5-FU and bevacizumab (Avastin(R)). The primary endpoint for the study is progression-free surviv...